Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ETHRANE vs BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Enflurane is a volatile inhalational anesthetic that potentiates GABA-A receptor activity and inhibits excitatory neurotransmission, resulting in general anesthesia.
Brompheniramine is a first-generation antihistamine that competitively inhibits histamine at H1 receptors, reducing allergic symptoms. Pseudoephedrine is a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction and nasal decongestion. Dextromethorphan is an NMDA receptor antagonist and sigma-1 receptor agonist that suppresses the cough reflex in the medulla oblongata.
Induction and maintenance of general anesthesia
Symptomatic relief of upper respiratory symptoms associated with allergic rhinitis, common cold, or sinusitis including nasal congestion, rhinorrhea, sneezing, and cough.
1-5% inspired concentration via inhalation, titrated to effect for maintenance of general anesthesia.
Adults and children ≥12 years: 1 tablet (brompheniramine maleate 4 mg, pseudoephedrine HCl 60 mg, dextromethorphan HBr 15 mg) orally every 4 hours, not to exceed 4 tablets in 24 hours, or 2 tablets (extended-release) every 12 hours, not to exceed 4 tablets in 24 hours.
Context-sensitive half-life: approximately 2-5 minutes after short procedures; prolonged after prolonged administration due to slow washout from fat stores.
Brompheniramine: 12-34 hours (mean ~24 h), prolonged in hepatic impairment. Pseudoephedrine: 5-8 hours (p H-dependent urinary excretion; alkaline urine prolongs half-life). Dextromethorphan: 3-4 hours (extensive metabolizers) or 18-24 hours (poor metabolizers of CYP2D6).
Primarily hepatic via cytochrome P450 (CYP2E1); minor metabolism to fluoride ions.
Brompheniramine: extensively metabolized via hepatic CYP450 (CYP2D6, CYP3A4) to desmethylbrompheniramine and other metabolites. Pseudoephedrine: partially metabolized via N-demethylation (CYP450) to norgseudoephedrine; 43-96% excreted unchanged. Dextromethorphan: primarily metabolized via CYP2D6 to dextrorphan (active), also via CYP3A4/5 to 3-methoxymorphinan.
Primarily exhaled unchanged via lungs (>95%); less than 5% metabolized in liver to fluoride ion and other metabolites, with renal excretion of metabolites.
Brompheniramine: Renal (approx. 80% as metabolites, <1% unchanged). Pseudoephedrine: Renal (70-90% unchanged, rest as metabolites). Dextromethorphan: Renal (primarily as metabolites, <1% unchanged). Biliary/fecal: Minor for all three.
Approximately 30-40%, primarily to albumin.
Brompheniramine: 60-80% (primarily albumin, alpha-1-acid glycoprotein). Pseudoephedrine: <10% (negligible). Dextromethorphan: 50-60% (possibly to albumin).
Vd: 1.2-2.0 L/kg, indicating extensive distribution into tissues, especially fat.
Brompheniramine: 7-10 L/kg (large, due to extensive tissue distribution). Pseudoephedrine: 2.5-3.5 L/kg (moderate, distributes into body water). Dextromethorphan: 3-5 L/kg (moderate, distributed to tissues including brain).
By inhalation: 100% as delivered; not administered orally.
Brompheniramine: ~70% (oral). Pseudoephedrine: 90-100% (oral). Dextromethorphan: ~10-30% (oral, due to extensive first-pass metabolism; in poor metabolizers, bioavailability higher).
No dose adjustment required for GFR >10 m L/min; use with caution in severe renal impairment (GFR <10 m L/min) due to potential accumulation of inorganic fluoride metabolites.
GFR ≥30 m L/min: No adjustment. GFR 10-29 m L/min: Administer every 6 hours; monitor for CNS effects. GFR <10 m L/min: Avoid use (risk of toxicity from pseudoephedrine and dextromethorphan accumulation).
No specific Child-Pugh based adjustment; use with caution in severe hepatic impairment as metabolism may be decreased.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce frequency (e.g., every 6 hours) and monitor for CNS depression. Child-Pugh C: Avoid use (dextromethorphan metabolism reduced; brompheniramine may accumulate).
Induction: 2-5% inspired concentration; Maintenance: 1-3% inspired concentration, adjusted to age and response.
Children 6-11 years: 1/2 tablet (brompheniramine maleate 2 mg, pseudoephedrine HCl 30 mg, dextromethorphan HBr 7.5 mg) orally every 4 hours, not to exceed 4 doses in 24 hours. Children 2-5 years: Not recommended (safety and efficacy not established). Children <2 years: Contraindicated (risk of respiratory depression).
Lower inspired concentrations (0.5-2%) recommended due to increased sensitivity and reduced clearance; titrate to effect.
Elderly >65 years: Initiate at lowest effective dose (e.g., 1/2 tablet) every 6-8 hours due to increased anticholinergic effects, hypotension, and CNS excitation. Maximum: 2 tablets in 24 hours. Monitor for confusion, urinary retention, and elevated blood pressure.
None
None.
May cause dose-dependent cardiovascular depression,Risk of malignant hyperthermia,Potential for nephrotoxicity due to fluoride release,Hepatotoxicity risk, especially with repeated use,Neurologic effects including seizure activity at high doses
Cardiovascular effects: hypertension, palpitations, tachycardia, arrhythmias, especially in patients with pre-existing heart disease or hyperthyroidism.,CNS depression: avoid concurrent use with alcohol or other sedatives; may impair mental/physical abilities.,Serotonin syndrome: risk with concomitant serotonergic drugs including MAOIs, SSRIs, SNRIs, triptans, linezolid, methylene blue.,QT prolongation: caution with drugs that prolong QT interval or predisposing conditions (e.g., electrolyte abnormalities, bradycardia).,Anticholinergic effects: caution in patients with glaucoma, prostatic hypertrophy, urinary retention, or asthma.,Inhibition of CYP2D6: dextromethorphan may increase levels of CYP2D6 substrates (e.g., TCAs, antipsychotics).
Known hypersensitivity to enflurane or other halogenated anesthetics,Known or suspected susceptibility to malignant hyperthermia,Severe hepatic impairment,Uncontrolled epilepsy
Hypersensitivity to any component,Concurrent use or within 14 days of MAO inhibitors (hypertensive crisis),Severe hypertension or coronary artery disease,Narrow-angle glaucoma,Urinary retention,During or immediately after treatment with serotonergic drugs (risk of serotonin syndrome)
No specific food interactions. Patient must follow preoperative fasting guidelines (nil per os, NPO) as directed by anesthesiologist to reduce risk of aspiration.
Avoid alcohol, which may potentiate CNS depression. Limit caffeine intake (coffee, tea, cola) as pseudoephedrine may increase stimulant effects. High-tyramine foods (e.g., aged cheese, cured meats, fermented products) may cause hypertensive crisis if combined with MAOIs, but this combination is contraindicated. No other significant food interactions.
FDA Category B. No evidence of teratogenicity in animal studies; human data limited. Use only if clearly needed during pregnancy, especially first trimester due to potential fetal hypoxia from maternal hypotension.
Brompheniramine: Limited human data; animal studies show no teratogenicity at clinically relevant doses. Pseudoephedrine: Case-control studies suggest small increased risk of gastroschisis and hemifacial microsomia with first-trimester use; vasoconstriction may reduce uteroplacental blood flow in third trimester. Dextromethorphan: No human teratogenicity data; animal studies show no fetal harm at therapeutic doses. Overall, combination is not recommended in first trimester; avoid in third trimester due to pseudoephedrine effects.
Excreted in breast milk in low amounts; M/P ratio not established. Consider benefits of breastfeeding vs. risk of infant exposure. Minimal systemic absorption in infant expected.
Brompheniramine: excreted in breast milk in small amounts; may cause infant irritability or drowsiness. Pseudoephedrine: concentrated in breast milk (M/P ratio ~3.0); may reduce milk production. Dextromethorphan: likely excreted in breast milk but no data on infant levels. Avoid during breastfeeding due to potential infant CNS effects and reduced milk supply.
No specific dose adjustments required for pregnancy; however, MAC decreases by approximately 30% during pregnancy due to hormonal changes and increased progesterone. Monitor depth of anesthesia closely.
No specific dose adjustments studied for combination in pregnancy. Due to increased plasma volume and clearance, standard adult doses may be less effective; however, avoid use in pregnancy due to risks. No PK studies available.
ETHRANE (enflurane) is a potent inhalation anesthetic. Its use is limited due to risk of seizures at high doses and potential for nephrotoxicity from fluoride ion release. Avoid in patients with history of seizures or renal impairment. Rapid induction and recovery; use with caution in hypotensive patients due to myocardial depression. Malignant hyperthermia trigger.
Do not use in children under 6 years due to risk of respiratory depression from dextromethorphan. Avoid in patients with hypertension or coronary artery disease due to pseudoephedrine. Brompheniramine has pronounced anticholinergic effects; use cautiously in elderly or those with glaucoma, urinary retention, or BPH. For severe cough, dextromethorphan efficacy is limited; consider if nonproductive cough is disruptive. Maximum duration of treatment is 7 days; prolonged use may lead to rebound congestion and dependence.
You will receive this anesthesia medication only in a hospital setting under expert supervision.,Possible side effects include nausea, vomiting, shivering, and confusion after waking up.,Tell your doctor if you have a history of seizures, kidney problems, or muscle disorders.,Avoid driving or operating machinery for at least 24 hours after anesthesia.,Do not eat or drink for the time specified by your healthcare team before surgery.
Do not take more than 6 doses in 24 hours. Do not exceed 7 days of use without consulting a doctor.,Avoid alcohol and other CNS depressants (e.g., sedatives, tranquilizers) as they may increase drowsiness.,Do not use if you have taken a monoamine oxidase inhibitor (MAOI) within the last 14 days.,Stop use and ask a doctor if symptoms do not improve within 7 days, are accompanied by fever, or if cough persists with headache, rash, or persistent headache.,Take with a full glass of water. May cause drowsiness; avoid driving or operating heavy machinery until you know how this medication affects you.,For the decongestant effect, take the last dose of the day several hours before bedtime to minimize insomnia.,Shake suspension well before use. Use only the dosing device provided.
No interactions on record
"Brompheniramine, a first-generation antihistamine, may inhibit the hepatic metabolism of sulfamethoxazole, a sulfonamide antibiotic, via competitive inhibition of cytochrome P450 enzymes, particularly CYP2C9. This results in elevated plasma concentrations of sulfamethoxazole, potentially increasing the risk of dose-dependent adverse effects such as hypersensitivity reactions, crystalluria, and hematologic toxicity (e.g., agranulocytosis). Clinically, patients may present with prolonged or intensified drug effects, including increased bone marrow suppression and renal impairment, especially in those with pre-existing hepatic or renal dysfunction."
"Dextropropoxyphene, an opioid analgesic, and brompheniramine, a first-generation antihistamine with anticholinergic properties, can synergistically depress the central nervous system (CNS) and respiratory centers. This interaction increases the risk of profound sedation, respiratory depression, coma, and death, particularly in elderly patients or those with pre-existing respiratory or hepatic impairment. Concurrent use also amplifies anticholinergic adverse effects such as urinary retention, constipation, and cognitive dysfunction."
"Brompheniramine, a first-generation antihistamine with significant central nervous system (CNS) depressant properties, can potentiate the CNS depressant effects of brimonidine, an alpha-2 adrenergic agonist used for ocular hypertension and glaucoma. This interaction leads to additive sedation, drowsiness, and dizziness, which may impair cognitive and motor function, increasing the risk of falls and accidents. Severe cases could result in excessive CNS depression, including somnolence and respiratory depression, particularly in elderly patients or those with compromised hepatic function."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ETHRANE vs BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE, answered by our medical review team.
ETHRANE is a General Anesthetic that works by Enflurane is a volatile inhalational anesthetic that potentiates GABA-A receptor activity and inhibits excitatory neurotransmission, resulting in general anesthesia.. BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE is a Sympathomimetic that works by Brompheniramine is a first-generation antihistamine that competitively inhibits histamine at H1 receptors, reducing allergic symptoms. Pseudoephedrine is a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction and nasal decongestion. Dextromethorphan is an NMDA receptor antagonist and sigma-1 receptor agonist that suppresses the cough reflex in the medulla oblongata.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ETHRANE and BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ETHRANE is: 1-5% inspired concentration via inhalation, titrated to effect for maintenance of general anesthesia.. The standard adult dose of BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE is: Adults and children ≥12 years: 1 tablet (brompheniramine maleate 4 mg, pseudoephedrine HCl 60 mg, dextromethorphan HBr 15 mg) orally every 4 hours, not to exceed 4 tablets in 24 hours, or 2 tablets (extended-release) every 12 hours, not to exceed 4 tablets in 24 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ETHRANE and BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ETHRANE is classified as Category C. FDA Category B. No evidence of teratogenicity in animal studies; human data limited. Use only if clearly needed during pregnancy, especially first trimester due to potential fetal . BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE is classified as Category A/B. Brompheniramine: Limited human data; animal studies show no teratogenicity at clinically relevant doses. Pseudoephedrine: Case-control studies suggest small increased risk of gastr. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.